Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, announced today the expansion of its global presence with the formation of Stemedica International S.A. headquartered in the Biopôle Technology and Business Park located in Epalinges, Switzerland near Lausanne.
San Diego, CA (PRWEB) April 9, 2009 -- Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, announced today the expansion of its global presence with the formation of Stemedica International S.A. headquartered in the Biopôle Technology and Business Park located in Epalinges, Switzerland near Lausanne. Biopôle is a state-of-the-art complex dedicated to attracting and supporting the expansion of global leaders in the bioscience and medical technology industries. The complex, adjacent to the University of Lausanne, overlooks beautiful Lake Geneva and the snow capped mountains of Switzerland and France. Owned by the State of Vaud, the City of Lausanne and the Municipality of Epalinges, the complex is operated as an independent corporation headed by a Board of Directors with both the vision and the experience to attract world leaders to this premiere complex.
"We invested significant time and effort in our search for a best-in-class stem cell company to become an integral part of our new technology complex. We are pleased to announce our engagement with Stemedica and we are lending our support in their plans to establish the largest manufacturing facility in the world for adult stem cell technology. Our flagship facility (see photo) is completed and the annex research building (housing Stemedica) is on schedule for completion in the fourth quarter of this year. With the expansion of the next 60,000 square feet, Stemedica will secure a significant presence in our new complex." stated Jean-Marc Tissot, Chairman of the Biopôle Board (www.biopole.ch).
"Stemedica is executing a dual-path strategy in which the Stemedica USA facility will continue to manufacture cGMP (Good Manufacturing Practices-Compliant) clinical grade stem cells as it works to gain the United States Food and Drug Administration's IND (investigational new drug) approval to begin clinical trials. Stemedica International will manufacture cGMP clinical grade stem cells to meet the ever-growing demand for clinical trials in Switzerland and other countries." noted Maynard Howe, PhD, Vice Chairman and CEO of Stemedica USA.
"This is an exciting time for Stemedica Cell Technologies. We have long felt that a strong, internationally-focused operation outside the United States was an important strategic step for the company. We are delighted with the reception that various government and business development agencies in Switzerland have provided to Stemedica. We are pleased to call Switzerland home for our business outside of the United States," said Roger Howe, PhD, Executive Chairman, Stemedica USA. "We're also extremely fortunate to have secured Frank Schuller, PhD as Chairman of Stemedica International. Along with his business acumen and international reputation, Frank brings a depth and breath of experience as well as governmental and financial networks critical to our global expansion."
Dr. Frank C. Schuller is Director of the Centre for Science and Society at Trinity College, Oxford. Dr. Schuller received an MBA and Doctorate from Harvard University where he also taught in the Business School and in the Kennedy School of Government. For the past ten years, Dr. Schuller has served as advisor and consultant to Swiss, German and Italian banks such as Hottinger & Cie, Credit Suisse, WestLB, Commerzbank and IMI. Working with Sir David Frost, Dr. Schuller also conducts a television interview series entitled, "Taking Stock" for financial channels such as CNBC, Bloomberg and several other cable outlets.
"I'm honored to be joining the Stemedica International Board and serving as its Chairman," said Dr. Schuller. "Stemedica has a unique opportunity to help change the face of medicine as we know it. The stem cell movement is upon us, and those companies who successfully combine scientific know-how with technological innovation, strong business development and management expertise will be the winners. I believe Stemedica is ideally suited to be one of those winners." Dr. Schuller went on to say, "It is extremely rewarding for me to be able to bring my international business development experience, as well as my professional and personal relationships, to ensure that Stemedica continues its leadership role in this rapidly emerging industry."
Stemedica International is also supported by the Economic Development (DEV) agency of the State of Vaud, Switzerland (www.dev.ch). Eric Maire, Senior Project Director noted that, "It is no secret that Switzerland is a world leader in economic performance, pharmaceutical and biotechnology, finance and banking. We are excited that Stemedica has chosen Switzerland and the State of Vaud as its international headquarters and we are working diligently to bring all of these key resources in support of their objectives. We are especially pleased that they will be continuing their research and collaborative relationships with several of our key universities including the University of Lausanne.
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, California.
Biopôle SA is a private company held by the State of Vaud (97.5%), the City of Lausanne (1.25%) and the Municipality of Epalinges (1.25%). Biopôle S.A. is the company in charge of developing, promoting, and managing the Biopôle Business Park.
The Biopôle Business Park is dedicated to the development of businesses operating in the biotechnology and medical fields. Located less than 2 hours from the principal European metropolitan centres, it offers some 80,000 m² [20 acres of greenfield site ripe for tailored development to suit the requirements of each occupier.
With world-renowned centres of excellence situated at less than 30 minutes' drive, the Biopôle site is particularly attractive for companies looking to establish a presence in Switzerland.
About DEV (Economic Development - State of Vaud)
Located in the geographic and economic heart of Europe, Switzerland offers many advantages to entrepreneurs. Enviable economic, political, and social conditions make Switzerland a highly advanced country in every way. As a world leader in economic performance, productivity, technology, finance and banking, Switzerland also enjoys one of the world's lowest tax rates. Switzerland has unparalleled economic, political and social stability. Switzerland recently signed a number of bilateral agreements with the European Union. Thus, the free movement of people, goods, services and most capital assets, has become much easier. However, by remaining outside of the European Union, Switzerland preserves all the benefits of independent decision-making. The canton of Vaud is in the heart of Switzerland within the heart of Europe, the canton of Vaud offers a dynamic economic and scientific climate in support of emerging businesses.
For more information regarding Stemedica Cell Technologies, Inc. or Stemedica International S.A. contact Dave McGuigan at dmcguigan (at) stemedica.com.
# # #
Read the full story at http://www.prweb.com/releases/stemedica-international/biopole-switzerland/prweb2311934.htm.
Copyright©2009 Vocus, Inc.
All rights reserved